MASI Stock Recent News
MASI LATEST HEADLINES
MASI, HOOD and DFS are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Masimo (MASI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the 46th Annual Raymond James Institutional Investor Conference on Tuesday, March 4, 2025 at 11:35 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces.
Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Masimo's fourth-quarter 2024 results continue to benefit from the strength in its Healthcare and Non-healthcare businesses.
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.